A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

Acute Myeloid Leukemia (AML) is a hematological malignancy characterized by the rapid, uncontrolled growth of immature myeloid cells, leading to bone marrow ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

International Childhood Cancer Day aims to spread awareness about childhood cancers. Childhood cancers (0-14 years of age) ...

Childhood cancer affects children under 18 and requires specialized treatment. Common types include leukemia, brain and ...

Cancer models developed with 3D bioprinting technology allow for rapid evaluation of individual drug responses.

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Holdings provides an update from the Company’s ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, a ...

Detailed price information for Aptevo Therapeutics Inc (APVO-Q) from The Globe and Mail including charting and trades.